New hope for ovarian cancer: targeted drug combo takes on Tough-to-Treat tumors
NCT ID NCT07504588
First seen Apr 04, 2026 · Last updated Jun 21, 2026 · Updated 9 times
Summary
This phase II trial tests whether a combination of two drugs—sacituzumab govitecan (a targeted therapy that delivers chemotherapy directly to cancer cells) and bevacizumab (which cuts off tumor blood supply)—works better than standard chemotherapy for women with platinum-sensitive ovarian cancer that has progressed after PARP inhibitor maintenance. The study will enroll 87 participants with BRCA mutations or homologous recombination deficiency. The main goal is to see if the new combo delays cancer growth longer than the standard approach.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT PLATINUM-SENSITIVE FALLOPIAN TUBE ENDOMETRIOID ADENOCARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
sacituzumab govitecan and bevacizumab
What this could lead to
If successful, this could offer a new treatment option for women with ovarian cancer that has returned after initial therapy and PARP inhibitor maintenance.
What could go wrong
This is a small, early-phase trial (87 participants) comparing a new drug combo to standard care. It may not show a clear benefit, and side effects from the experimental drugs are possible.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.